Only two patients discontinued treatment with an aLHRH following ovarian adnexectomy: one due to synchronous ovarian carcinoma, and one as prophylaxis due to a pathogenic BRCA1/2 mutation. Here, BRCA1 is linked to ovarian carcinoma.